Physician profile
Allison Stoecker
NPI 1720436397
$1,791.91
in general payments reported to CMS, 2019-2025
15 companies · $90.79 in 2025
The $90.79 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $87.94 · 2021: $38.23 · 2022: $151 · 2023: $504 · 2024: $81.82 · 2025: $90.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.43 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $446.05 | 2019 | |
| Abbvie INC. | $385.79 | 2019-2025 | Skyrizi |
| Merz North America, INC. | $250.00 | 2023 | Xeomin |
| Sun Pharmaceutical Industries INC. | $200.18 | 2019-2023 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $143.91 | 2019-2024 | Libtayo |
| Lilly USA, LLC | $91.78 | 2019-2024 | Ebglyss, Taltz |
| Janssen Scientific Affairs, LLC | $76.85 | 2023 | Tremfya |
| Leo Pharma INC. | $43.44 | 2019-2025 | Anzupgo |
| Galderma Laboratories, L.P. | $27.73 | 2019 | |
| Celgene Corporation | $24.87 | 2019 | |
| Janssen Biotech, INC. | $23.05 | 2025 | Tremfya |
| Dermira, INC. | $22.00 | 2019 | |
| Amgen INC. | $20.81 | 2022 | |
| Kerecis Limited | $19.61 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Pfizer INC. | $15.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Stoecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.